Related by context. All words. (Click for frequent words.) 66 progression TTP 64 mCRPC 63 prospectively defined 62 4mg/kg 62 efficacy evaluable 62 CRp 62 FOLFIRI alone 62 CR nPR 62 refractory colorectal cancer 61 Free Survival PFS 61 prospectively stratified 61 EGFR mutation positive 61 microbiologically evaluable 61 Median PFS 61 Secondary endpoints included 61 non squamous histology 60 #mg QD [002] 60 antiretroviral naïve 60 HAQ DI 60 nonmetastatic 60 CCyR 60 morphometric vertebral fractures 60 tumor progression TTP 60 #mg QD [001] 60 virological response 60 sipuleucel T 60 tumor histology 59 certolizumab 59 treatment naive genotype 59 FOLFIRI 59 8mg/kg 59 % CI #.#-#.# [007] 59 FOLPI 59 Secondary endpoints include 59 Acute Coronary Syndromes ACS 59 antiangiogenic therapy 59 null responder HCV 59 SIMPADICO 59 de novo AML 59 biliary tract cancer 59 CIMZIA TM certolizumab pegol 59 ADAS cog 59 achieved statistical significance 59 mcg BID 59 BEACOPP 59 recurrent GBM 59 tipranavir ritonavir 59 null responder 59 SVR# 59 splenectomized patients 59 CLL SLL 59 desvenlafaxine succinate 59 remission CR 58 adjuvant cisplatin 58 % CI #.#-#.# [003] 58 underwent resection 58 CC genotype 58 Kaplan Meier curves 58 haematologic 58 VcMP 58 localized renal 58 QTcF 58 periprocedural MI 58 PEG IFN 58 mg QD 58 adverse cytogenetics 58 methotrexate monotherapy 58 noninferior 58 nonmetastatic prostate cancer 58 mg p = 58 opioid naive 58 doxorubicin docetaxel 58 achieved CCyR 58 estramustine 58 perioperative complications 58 concurrent chemoradiation 58 demonstrated clinically meaningful 58 attain statistical significance 58 completely resected 58 median PFS 58 papillary renal cell carcinoma 58 prespecified secondary 58 dosage regimens 58 tumor regressions 58 lymphocytosis 58 DAS# remission 58 Kaplan Meier analysis 58 genotypic resistance 58 clinically meaningful improvement 58 noninferiority 58 adefovir treated 58 preoperative chemotherapy 58 achieved sustained virological 58 achieved ACR# 58 Y BOCS 58 confirmed CCyR 57 randomized #:#:# 57 bladder carcinoma 57 null responders 57 P = .# 57 recurrent glioblastoma multiforme 57 OSAHS 57 renal cysts 57 T2DM 57 paclitaxel eluting stents 57 DLTs 57 deep venous thromboses 57 ovarian carcinoma 57 relapsed MM 57 pT3 57 eribulin mesylate 57 asymptomatic metastatic 57 F FDG PET 57 CORE OM 57 mean ± SEM 57 follicular lymphoma FL 57 prognostic indicators 57 CIBIC plus 57 NIHSS 57 affective psychosis 57 Evaluable 57 liver metastasis 57 QTc 57 remission induction 57 Primary endpoints 57 HCV genotype 57 androgen suppression 57 hematopoietic cancers 57 thyroid carcinoma 57 nonrandomized 57 Acute renal failure 57 partial remissions 57 KRAS mutant tumors 57 antiarrhythmic drug 57 irinotecan cisplatin 57 Neuropsychiatric Inventory NPI 57 complete cytogenetic response 57 sirolimus eluting stents 57 p = .# [002] 57 galiximab 57 naïve HCV 57 abacavir lamivudine 57 hepatitis C genotype 56 pCR 56 T1a 56 operable breast cancer 56 PASI scores 56 antiretroviral naive 56 evaluable 56 visceral metastases 56 metastatic neuroendocrine tumors 56 severe neutropenia 56 prednisone prednisolone plus 56 histologic subtype 56 nondiabetic patients 56 postintervention 56 undetectable HBV DNA 56 CR CRu 56 metastatic GIST 56 rhGH 56 linaclotide treated 56 bortezomib refractory 56 Flu Cy 56 Viral load 56 ADCS CGIC 56 BARACLUDE ® 56 NNT = 56 Newly Diagnosed Multiple Myeloma 56 HBeAg seroconversion 56 HLA DR4 56 Subgroup analysis 56 mg administered orally 56 neoadjuvant treatment 56 serum phosphorous 56 Teriflunomide 56 biochemical relapse 56 sustained virological response 56 unfavorable cytogenetics 56 intermittent dosing 56 tolterodine ER 56 virologic failure 56 Stent thrombosis 56 confidence interval #.#-#.# 56 nonresponders 56 Unstable Angina 56 baseline LDH 56 Folfox 56 comparator arm 56 atazanavir ritonavir 56 DAS# scores 56 mg/# mL [001] 56 NIH CPSI 56 WOMAC pain 56 mutated K ras 56 REMINYL ® 56 ug dose 56 liver histology 56 dalteparin 56 oral antidiabetic medication 56 piperacillin tazobactam 56 pT2 56 nicardipine 56 heavily pretreated 56 elevated LDH 56 AST ALT 56 clinicopathological features 56 locoregional recurrence 56 relapsing multiple sclerosis 56 nomograms 56 anagrelide 56 corrected QT interval 56 undergoing liver transplantation 56 lesional 56 small lymphocytic lymphoma 56 TURBT 56 elevated transaminases 56 -#.# log# copies mL 56 refractory NSCLC 56 florbetaben 56 neoadjuvant 56 prostate carcinoma 56 Pharmacokinetics PK 56 immunomodulatory therapy 56 mitoxantrone plus 56 atherothrombotic 56 Brief Psychiatric 56 Score TOS 56 TWYNSTA 56 #mg BID [001] 56 Tasigna prolongs 56 Sipuleucel T 56 MADRS score 56 patientswith 56 NMIBC 56 metastatic malignant 56 carotid plaque 55 mITT population 55 recurrent glioblastoma 55 pharmacokinetic parameters 55 virologic response 55 biochemical recurrence 55 epoetin alpha 55 BENICAR HCT 55 mg ustekinumab 55 KRAS mutations occur 55 statistically significant p = 55 BR.# 55 amisulpride 55 histological subtype 55 TIMP 1 55 multivariate analyzes 55 underwent surgical resection 55 Postoperatively 55 cytogenetic abnormalities 55 antiandrogen 55 pharmacodynamic parameters 55 octreotide LAR 55 HSCT 55 cisplatin chemotherapy 55 EBMT criteria 55 PSA nadir 55 epithelial tumors 55 multivariate Cox 55 colorectal adenoma 55 UA NSTEMI 55 histologically confirmed 55 RECIST criteria 55 confidence interval CI 55 squamous histology 55 relapsers 55 radical prostatectomy RP 55 #mg/day [001] 55 chemoradiation therapy 55 infliximab monotherapy 55 bronchial hyperresponsiveness 55 receiving highly emetogenic 55 Kaplan Meier estimates 55 INVEGA ® 55 metastatic malignant melanoma 55 dose cohort 55 Cimzia TM 55 tapentadol ER 55 Refractory Hodgkin Lymphoma 55 urodynamic parameters 55 XIENCE V demonstrated 55 BARACLUDE r 55 Multiple Ascending Dose 55 PCNSL 55 Prognostic factors 55 APTIVUS r 55 NSTEMI 55 clodronate 55 endometrioid 55 MGd 55 RLAI 55 VADT 55 extensive metabolizers 55 IIIa inhibitor 55 neovascular 55 fludarabine cyclophosphamide 55 mesalamine granules 55 placebo p = 55 HBeAg negative 55 liver transaminases 55 HER2 expression 55 doxorubicin cyclophosphamide 55 radiographic progression 55 DAS# CRP 55 posttreatment 55 Rate ORR 55 Edge STudy 55 bivariate 55 thromboembolic events 55 debulking surgery 55 DMARD 55 histologically proven 55 XIENCE V PROMUS Stent 55 dosing cohorts 55 multivariable adjusted 55 ANCOVA 55 Cytogenetic 55 Pharmacokinetic studies 55 ß blockers 55 mg/m2 dose 55 clinically evaluable 55 flutamide 55 hemoglobin A1c levels 55 EDSS score 55 free survival PFS 55 SVR4 55 periprocedural 55 randomisation 55 serum urate 55 subgroup analyzes 55 oxycodone CR 55 tumor xenograft models 55 endoscopic ultrasonography 55 pretreatment serum 55 rtPA 55 venlafaxine XR 55 titrated glipizide 54 achieved PASI 54 daily subcutaneous injections 54 response CCyR 54 PegIFN 54 calcium antagonist 54 EXJADE 54 stage IIIB 54 stratifying patients 54 RECIST Response Evaluation Criteria 54 intact parathyroid hormone 54 PSADT 54 mild renal insufficiency 54 poststroke 54 Pain Rating Scale 54 Scale EDSS 54 budesonide pMDI 54 nodal metastasis 54 ischemic lesions 54 androgen ablation 54 Posaconazole 54 Soft Tissue Sarcoma 54 CYP#D# genotype 54 ipsilateral breast 54 pretransplant 54 % CI #.#-#.# [008] 54 serum HBV DNA 54 neurologic progression 54 mRS 54 choroidal vasculopathy 54 moderate renal impairment 54 extracapsular extension 54 chlorambucil 54 neutrophil counts 54 plasma pharmacokinetics 54 gefitinib Iressa 54 Partial Response 54 ACTEMRA TM 54 adjuvant tamoxifen 54 antiplatelet drugs 54 viral kinetics 54 chemosensitivity 54 restenotic lesions 54 Myelodysplastic Syndrome 54 Timed Walk 54 HCV SPRINT 54 prostate cancer CaP 54 EDSS scores 54 cytopenias 54 HbA 1c levels 54 CK # plasma concentrations 54 rebleeding 54 IPAH 54 Preoperatively 54 mCRC patients 54 aromatase inhibitor therapy 54 tirofiban 54 dosing cohort 54 SCr 54 prespecified 54 Known hypersensitivity 54 locoregional disease 54 LVSD 54 carcinoids 54 Univariate analysis 54 plus MTX 54 locoregional 54 pegylated liposomal doxorubicin 54 leucopenia 54 -#.# log# 54 detectable HCV RNA 54 KRAS wild 54 annualized relapse 54 mg clopidogrel 54 oncological outcomes 54 intravenous dosing 54 6MWD 54 Operative mortality 54 divalproex sodium 54 KRAS mutation 54 conjugated equine estrogen 54 oral rivaroxaban 54 papillary thyroid carcinoma 54 lumbar spine BMD 54 melphalan prednisone 54 K ras mutations 54 Kaplan Meier method 54 #mg BID [003] 54 Thal Dex 54 paclitaxel carboplatin 54 Pharmacokinetic 54 darunavir r 54 Histologic 54 aMCI precursor 54 esophageal carcinoma 54 virologic responses 54 CI #.#-#.# p = 54 T#I [002] 54 STRIDE PD 54 neutropenic fever 54 p = NS 54 subscore 54 hematological relapse 54 cisplatin vinorelbine 54 relapsed AML 54 PCWP 54 stage IIIb IV 54 confidence intervals CIs 54 low dose cytarabine 54 Psoriasis Area 54 trials RCTs 54 clinicopathologic 54 receiving golimumab 54 timepoints 54 teriflunomide 54 QD dosing 54 tigecycline 54 rFVIIa 54 atherosclerotic renal artery stenosis 54 oblimersen 54 paricalcitol 54 androgen independent 54 Hazard Ratio HR 54 femoral neck fracture 54 spirometric 54 EDEMA3 trial 54 renal cortical 54 oral anticoagulation 54 mcg doses 54 adjunctive ABILIFY 54 pamidronate 54 RAPAFLO R 54 urinary N telopeptide 54 BEXXAR Therapeutic Regimen 54 virologic suppression 54 mcg QD 54 events TEAEs 54 de novo kidney transplant 54 % Confidence Interval 54 Response Evaluation Criteria 54 M#V 54 fibrinolytic therapy 54 HbA1C levels 54 evaluable patients 54 Platelet counts 54 tipranavir r 54 PRADAXA #mg 54 histologic findings 54 anemia hemoglobin 54 hepatocellular carcinomas 54 Multiple Myeloma MM 54 echocardiographic parameters 54 posttransplant 54 median survivals 54 ER CHOP 54 5-FU/LV 54 castrate resistant 54 methotrexate therapy 54 HBeAg negative patients 54 mucosal healing 54 CSBM 54 Montgomery Asberg Depression 54 NSTE ACS 54 Helicobacter pylori eradication 54 CHOP chemotherapy 54 elevated IOP 54 sacral neuromodulation 54 moderately emetogenic 54 CTEPH 54 COPERNICUS 54 Baseline characteristics 54 anthracycline chemotherapy 54 intratympanic 54 serum ALT 54 NATRECOR R 54 β blockers 54 stage IIIA 54 postoperative radiotherapy 54 gadolinium enhanced 54 NNRTI resistance 54 μmol L 54 intraperitoneally 54 suboptimal adherence 54 urothelial carcinoma 54 ziprasidone 54 substudy 54 univariate analysis 53 preoperatively 53 TDF FTC 53 hepatic insufficiency 53 Relapsing Remitting Multiple Sclerosis 53 CI -#.# 53 T2 lesions 53 beta blocker therapy 53 RARP 53 oral diclofenac 53 sternal wound infections 53 TOP2A 53 NMDA antagonists 53 FDG PET imaging 53 gastric adenocarcinoma 53 metastatic lymph nodes 53 abatacept 53 nucleoside naive 53 lamivudine refractory patients 53 IFN beta 53 dose escalation phase 53 microbiological eradication 53 ETDRS 53 SSRI SNRI 53 #Gy 53 CARE HF 53 paroxysmal AF 53 ADAS Cog 53 Kaplan Meier estimate 53 monophasic 53 immunohistochemical analysis 53 transrectal ultrasound guided 53 multivessel disease 53 dose regimens 53 Papillary 53 SORT OUT III 53 interquartile range 53 xenograft models 53 undergoing radical cystectomy 53 baseline HbA1c 53 Health Assessment Questionnaire 53 non valvular atrial 53 DXA scan 53 ALT flares 53 n = 53 beta1 53 active comparator 53 interstitial brachytherapy 53 plus prednisone 53 ritonavir boosted 53 CIMZIA R 53 Idiopathic Pulmonary Fibrosis 53 corticosteroid dose 53 Peg IFN 53 secondary efficacy endpoints 53 plasma HCV RNA 53 TIMP 53 overt nephropathy 53 seminal vesicle invasion 53 LDH lactate dehydrogenase 53 ATACAND 53 BPS IC 53 hematologic toxicity 53 amnestic MCI 53 transdermal estradiol 53 somatostatin analog 53 surgically resected 53 LEXIVA r 53 Plaque Psoriasis 53 intraobserver 53 AA Amyloidosis 53 intravitreal injections 53 macroalbuminuria 53 radiotherapy RT 53 % CI #.#-#.# [005] 53 ascending doses 53 Observational Study 53 syndromal 53 lactate dehydrogenase LDH 53 mitoxantrone 53 clinicopathological 53 renal tumors 53 mg kg dose 53 TEAEs 53 Severity Index PASI 53 resected pancreatic cancer 53 autologous SCT 53 biopsy Gleason 53 RhuDex TM 53 See CLINICAL PHARMACOLOGY 53 ‰ ¥ 53 univariate analyzes 53 antidepressant monotherapy 53 gadolinium enhancing 53 pharmacodynamic PD 53 mL/min/#.# m 2 53 IFN α 53 ECOG PS 53 statistical significance p 53 hyperacute 53 CrCl 53 lymphadenectomy 53 osteopenic 53 antibody titer 53 hepatic metastases 53 multicenter randomized controlled 53 % CI #.#-#.# [006] 53 ALT elevations 53 ADCS ADL 53 hip BMD 53 anticholinergic agents 53 Kaplan Meier curve 53 Bosentan 53 Crohn Disease Activity 53 patients evaluable 53 atorvastatin #mg 53 Visual Analogue Scale VAS 53 univariate 53 ipsilateral stroke 53 vinorelbine 53 aMCI 53 intratumoral 53 plus octreotide LAR 53 μg kg 53 sUA 53 generalized anxiety disorder GAD 53 p = #.# [003] 53 hematological parameters 53 binary restenosis 53 HIV HCV coinfected 53 conventional DMARDs 53 artery stenosis 53 IU ml 53 Stage IIIb 53 acute myeloid 53 preoperative intraoperative 53 pancreatic adenocarcinoma 53 clinically meaningful improvements 53 ACR# responses 53 CI #.#-#.# [002] 53 adriamycin 53 median CD4 53 evaluable subjects 53 intradermal injections 53 platelet reactivity 53 pharmacodynamics PD 53 prospective nonrandomized 53 Secondary efficacy endpoints 53 myocardial infarctions MIs 53 adjunctive placebo 53 myocardial infarctions 53 surgical debulking 53 ARCOXIA 53 abdominal pain abdominal discomfort 53 virological failure 53 Lymph node 53 SSc 53 fusion enhancers 53 pancreatic ductal adenocarcinoma 53 highly emetogenic 53 β blocker 53 CYP #D# 53 leukocytosis 53 prospectively randomized 53 % CI #.#-#.# [001] 53 Ischemic 53 serologically active patients 53 mITT 53 concomitant medications 53 #mg/m# [002] 53 hepatectomy 53 ribavirin RBV 53 cardiac repolarization 53 viral tropism 53 Capesaris 53 endometrial thickness 53 hematologic abnormalities 53 HLA DR2 53 electrophysiologic 53 QRS duration 53 Active Ulcerative Colitis 53 HGD 53 NAbs 53 choroidal neovascularization 53 EQ 5D 53 mg TID 53 MoxDuo TM IR 53 cranial irradiation 53 scintigraphic 53 Visual acuity 53 Non inferiority 53 thienopyridine 53 pharmacokinetics PK 53 relapsed CLL 53 relapsed SCLC 53 recurrent ischemia 53 HIV RNA 53 cisplatin resistant 53 Sustained virologic response 53 Kaplan Meier survival 53 radiographic findings 53 insulin detemir 53 mg RDEA# 53 intracranial hemorrhage ICH 53 pancreatic neuroendocrine tumors 53 symptomatic VTE 53 oxycodone IR 53 ezetimibe simvastatin 53 cutaneous melanoma 53 lispro 53 LV ejection fraction 53 autoantibody levels 53 cytogenetic responses 53 antioxidant supplementation 53 secondary efficacy endpoint 53 postop 53 febrile neutropenia 53 COPAXONE 53 FOLFOX4 53 saline placebo 53 EURIDIS 53 transaminase levels 53 oral Hycamtin 53 thrombocytopenic 53 primary percutaneous coronary 53 sonographically guided 53 gastroduodenal 52 headache nasopharyngitis 52 intraperitoneal 52 adalimumab 52 Oracle DB2 Sybase 52 definite stent thrombosis 52 Thrombolysis 52 log# IU mL 52 rFSH 52 bosentan 52 Fingolimod 52 Montgomery Åsberg Depression 52 preoperative PSA 52 glulisine 52 dasatinib Sprycel 52 radical nephrectomy 52 glycoprotein IIb IIIa inhibitors 52 nonsignificant 52 postoperatively 52 guideline concordant 52 HRCT 52 HER2 amplification 52 plus methotrexate 52 nonvertebral fractures 52 prostatic adenocarcinoma 52 NPH insulin 52 postoperative AF 52 PCa 52 sustained virologic response 52 ARB telmisartan 52 prodromal symptoms 52 urothelial 52 HER2 negative 52 peginterferon alpha 52 Symptom severity 52 pegylated interferon alfa 2b 52 oncologic outcomes 52 Adenomas 52 plus medroxyprogesterone acetate 52 reinfarction 52 CIMZIA TM 52 Randomized Evaluation 52 IFN alfa 52 gadobutrol 52 plus OBT 52 placebo PBO 52 HER2 overexpression 52 APTIVUS ritonavir 52 inflammatory lesions 52 LVEF 52 prior chemotherapy regimens 52 neoadjuvant chemotherapy 52 lipid lowering agents 52 advanced adenoma 52 MMSE score 52 retrospectively analyzed 52 antithymocyte globulin 52 prophylactic cranial irradiation 52 achieved sustained virologic 52 Mantel Haenszel 52 tumor necrosis 52 autoantibody positive 52 undetectable HCV RNA 52 ACR Pedi 52 poor metabolizers 52 prostate cancer PCa 52 nasal polyposis 52 odds ratios ORs 52 biologic DMARD 52 Cmax 52 coinfected patients 52 log# reduction 52 clinically meaningful differences 52 GAMMAGARD 52 Systemic Sclerosis 52 venous thromboembolic disease 52 baseline FEV 52 subcutaneous methylnaltrexone 52 LV dysfunction 52 Rating Scale MADRS 52 FDG uptake 52 receiving APTIVUS r 52 Afib 52 Myelodysplastic Syndrome MDS 52 ACR# response 52 castrate resistant prostate cancer 52 generalized edema 52 p# biomarker 52 TAXUS Express Stent 52 polyposis 52 Hb A1C 52 irbesartan 52 GH deficiency 52 Antiviral Therapy 52 Index CDAI 52 perioperatively 52 hematologic adverse 52 undergoing percutaneous coronary 52 chemoradiotherapy 52 receiving INTRON 52 external beam radiotherapy 52 Glioblastoma Multiforme GBM 52 abnormal cytology 52 sonographically 52 alanine aminotransferase ALT 52 hepatic arterial 52 leiomyomas 52 myocardial revascularization 52 serum aminotransferase levels 52 mCi kg 52 Surgical resection 52 invasive carcinomas 52 angiographically 52 Main Outcome Measure 52 ispinesib administered 52 glycosylated hemoglobin levels 52 ALB # 52 sarcomatoid 52 tophi 52 progesterone receptor negative 52 QTc intervals 52 GG genotype 52 breast carcinomas 52 surgically resectable 52 BENICAR 52 TPV r 52 perfusion abnormalities 52 HbA 1c 52 hormone refractory 52 cystoid macular edema 52 DES implantation 52 MIRAPEX 52 spontaneous bowel movements 52 intravesical therapy 52 APTIVUS R 52 absolute lymphocyte 52 symptomatic paroxysmal AF 52 thyroglobulin 52 progesterone receptor PR 52 NYHA functional class 52 Kaplan Meier 52 WOMAC scores 52 receiving ISENTRESS 52 prognostic variables 52 Pegasys plus Copegus 52 recurrent venous thromboembolism 52 APPRAISE 52 VFEND 52 Phase IIA 52 severe hepatic dysfunction 52 dyspareunia 52 PsA 52 breast carcinoma 52 CLINICAL PHARMACOLOGY 52 receiving prophylactic anticoagulation 52 lung metastases 52 CI #.#-#.# [001] 52 hemodialysis patients 52 hepatic fibrosis 52 Arranon 52 #.#/#.# mmHg [001] 52 orthotopic 52 timepoint 52 severe exacerbations 52 anemia neutropenia 52 normal karyotype 52 laboratory abnormalities 52 receiving VICTRELIS 52 μg dose 52 receiving TNF blockers 52 DAPT 52 PANSS scores 52 YMRS 52 plasma uric acid 52 death reinfarction 52 maximal dose 52 TNM staging 52 Suicidal ideation 52 MACCE 52 ribavirin therapy 52 Gleevec resistant 52 nonadherent 52 MEND CABG II 52 epoetin beta 52 Hazard Ratio = 52 hepatic enzymes 52 sirolimus stent 52 leukopenia 52 observational cohort study 52 androgen deprivation 52 Pegylated Liposomal Doxorubicin 52 oral moxifloxacin 52 multivariable Cox 52 radiographic outcomes 52 hormone receptor negative 52 euthyroid 52 PANSS 52 EGFR mutation status 52 HCV genotype 1 52 caspofungin 52 Kinoid 52 medically inoperable 52 ORACLE MS 52 logistic regression analyzes 52 ErbB2 positive 52 weekly subcutaneous injections 52 albumin excretion rate 52 PLX STROKE targeting 52 TLR antagonist 52 FDG PET scans 52 opioid naïve 52 paroxysmal atrial fibrillation 52 endoscopic remission 52 dopaminergic therapy 52 NSCLC tumors 52 CD# expression [002] 52 P ≤ 52 postprocedure 52 XELOX 52 clomipramine 52 renal pelvis 52 interobserver 52 FAMPYRA 52 endobronchial 52 amoxicillin clavulanate 52 urine cytology 52 HBeAg positive patients 52 nonadherence 52 Carotid endarterectomy 52 mg BID dose 52 resectable 52 atrioventricular block 52 microvessel density 52 QIDS SR 52 pelvic lymphadenectomy 52 adjuvant systemic 52 anastomotic leak 52 prospective multicentre 52 histologies 52 CANCIDAS 52 rapid virologic response 52 Subgroup analyzes 52 breast cancer subtypes 52 = #.#-#.# 52 systolic dysfunction 52 Fibromyalgia Impact Questionnaire 51 CsA